https://www.selleckchem.com/products/shield-1.html
1 years); all 18 completed. Seventy percent took concurrent immunosuppression. Reported compliance was 99% in part B. Two subjects reported adverse events deemed related-one in part A with eructation, flatulence, and reflux; one in part B with dizziness, abdominal pain, and headache. No serious adverse events were reported. There was no significant change in median calprotectin across part B (87.8 [4.4-447] to 50.5 [5.3-572], P = 0.44 by the Fisher exact test in the active group). No significant differences were found in microbiota
Like
Comment
Share
